Skip to main content

Table 1 Patients’ characteristics

From: The prognostic significance of the advanced lung cancer inflammation index in patients with unresectable metastatic colorectal cancer: a retrospective study

Age (years)
 Median (range) 65 (18–89)
Gender
 Male 87
 Female 72
Performance status
 0 139
 1 17
 2 3
Location of primary tumor
 Right side 39
 Left side 120
Histological type
 Well, Moderately 142
 Poorly, Mucinous 17
RAS status
 Wild type 63
 Mutant type 54
 Unknown 42
Detection of unresectable tumor
 Synchronous 106
 Metachronous 53
Number of organs affected by metastasis
 One organ 106
 Multiple organs 53
Peritoneal dissemination
 Negative 124
 Positive 35
First-line chemotherapy regimen
 FOLFOX 74
 CapeOX 52
 FOLFIRI 25
 SOX 8
Molecular-targeted therapy
 Bevacizumab 85
 Cetuximab 11
 Panitumumab 7
 None 56
BMI (kg/m2)
 Median (range) 21.71 (15.30–33.76)
Serum albumin concentration (g/dl)
 Median (range) 3.9 (2.5–4.9)
NLR
 Median (range) 2.41 (0.58–13.56)
ALI
 Median (range) 37.92 (4.61–175.07)
  1. FOLFOX 5-fluorouracil+leucovorin+oxaliplatin, CapeOX Capecitabine+oxaliplatin, FOLFIRI 5-fluorouracil+leucovorin+irinotecan, SOX S-1 + oxaliplatin, NLR Neutrophil-to-lymphocyte ratio, ALI Advanced lung cancer inflammation index, BMI Body mass index